Positron Emission Tomography Neuro-Imaging

Sean L. Kitson*

Department of Biocatalysis and Isotope Chemistry, Almac, 20 Seagoe Industrial Estate, Craigavon, BT63 5QD, UK

ABSTRACT

Positron Emission Tomography (PET) is a powerful imaging technique exploring in vivo brain functions. Today PET is becoming an essential tool in specialist clinical neurology settings particularly for diagnosing Alzheimer’s, Parkinson’s and epilepsy disease states. This inaugural article aims to deliver a brief insight into PET techniques in the diagnosis of neurological diseases including multiple sclerosis.

KEYWORDS: Radiotracer, Positron Emission Tomography (PET), Neurology, Alzheimer’s disease, Parkinson’s disease, Epilepsy, Multiple sclerosis

INTRODUCTION

The imaging of the human body can be traced back to 1895 with the discovery of x-rays by the 1901 Nobel Laureate Wilhelm Conrad Röntgen. Currently a variety of imaging techniques are used to effectively assist the diagnosis of disease in humans. These include Computed Tomography (CT), Magnetic Resonance Imaging (MRI) and Single Photon Emission Computed Tomography (SPECT) all capable of generating 3-D anatomical images of the human body. Since the 1990s a revolutionized imaging tool for Nuclear Medicine has emerged called Positron Emission Tomography (PET).

PET, in contrast to other conventional imaging techniques, provides an insight into the biochemical/physiological processes of the human body. The biochemistry of the body is altered when it is in a disease state. For example, PET imaging has the capability to detect certain cancer stages before apparent structural changes appear, whereas MRI is unable to see these subtle changes. PET utilizes ‘positron’ emitting radiotracers to deliver images of the human body.

These radiotracers must be synthesized very quickly due to the short half-life of the nuclide ($t_{1/2}\text{<}20\text{mins for carbon-11}; t_{1/2}\text{<}110\text{mins for fluorine-18}$).

Non-invasive PET imaging has been used as a research tool since the 1970s. By the 1990s this advance in technology aided the diagnosis, staging and monitoring of disease states in patients. In 1953, the pioneering work of Brownell and Sweet at Massachusetts General Hospital allowed the completion of the first positron detector to study brain function. The earliest clinical applications were carried out in 1988 to diagnose cancers of the head-and-neck.
PET radiotracers have been developed to study the role of dopamine and serotonin neurotransmission processes in the brain. These radiotracers have probed the areas of the brain and Central Nervous System (CNS) for storage, re-uptake, post-synaptic binding and signaling mechanisms. Research continues to develop diagnostic imaging in the area of PET-immunology which target monoclonal antibodies towards tumor associated antigens. The design of PET [18]F Reporter Probes such as Fluoropenciclovir (FPCV) has been developed to image Herpes Simplex Virus type-1 and thymidine kinase (HSV1-tk) for reporter expression. Other research areas include the use of PET imaging to track the transplantation of stem cells into diseased areas of myocardial infarction and also in Parkinson’s disease. This enables the detection and monitoring of the functions of newly transplanted stem cells.

Currently, commercial multi-ring PET scanners have enhanced spatial resolution of detection with less than 5mm coupled with a greater sensitivity, axial coverage and increased image volume. The spatial resolution of PET is less than that of CT and MRI. This allows for whole-body PET studies to be carried out rapidly. The future role of PET imaging is pivotal in the organization of ‘personalized medicine’ by routinely screening and monitoring malignant disease states. According to Ronald L van Heertum MD of the University of Columbia, “PET is revolutionizing the fields of oncology, cardiology, neurology, and psychiatry, with a major impact on patient management.”

PET NEURO-IMAGING

The basic principle of PET neuro-imaging is based on an assumption that high areas of radioactivity are related to brain activity. This activity can be evaluated by measuring the blood flow to various regions of the brain by administering the radiotracer [O15] oxygen. The disadvantage of using this radiotracer is its relatively short half-life of approximately 2 minutes. Therefore, on its output from the cyclotron it must be immediately transported and administered to the patient. In this article various radiotracers are discussed to circumvent these limitations in the diagnosis of Alzheimer’s, Parkinson’s, epilepsy and multiple sclerosis.

Alzheimer’s disease

PET-amyloid plaque imaging with Pittsburgh Compound-B is shown to have a higher accumulation in subjects diagnosed with Alzheimer’s disease compared to patients with no dementia. Most importantly, Pittsburgh Compound-B confirms the existence of Aβ plaques prior to the onset of dementia. This tracer is able to detect preclinical Alzheimer’s disease pathology with the same accuracy as seen in post-mortem examinations.

PETamyloid imaging agent Vizamyl® (flutemetamol). This imaging agent differs slightly from the other FDA approval (April 2012) of Amyvid® because it is used to evaluate the density of plaques using a colour-calibrated scale of signal intensity.

In October 2013 the FDA gave approval to the amyloid [18]F PET imaging agent Vizamyl® (flutemetamol). This imaging agent differs slightly from the other FDA approval (April 2012) of Amyvid® because it is used to evaluate the density of plaques using a colour-calibrated scale of signal intensity.

Consequently, Amyvid® was approved using a grayscale. Amyvid®, like Pittsburgh Compound-B binds to beta-amyloid. However due to its longer half-life of 110 minutes it was found to accumulate more in the brains of people with Alzheimer’s disease, particularly in the regions known to be associated with beta-amyloid deposits.

Parkinson’s disease

PET imaging with Pittsburgh Compound-B is shown to have a higher accumulation in subjects diagnosed with Parkinson’s disease compared to patients with no dementia. Most importantly, Pittsburgh Compound-B confirms the existence of Aβ plaques prior to the onset of dementia. This tracer is able to detect preclinical Alzheimer’s disease pathology with the same accuracy as seen in post-mortem examinations.

PET-amyloid plaque imaging with Pittsburgh Compound-B is shown to have a higher accumulation in subjects diagnosed with Alzheimer’s disease compared to patients with no dementia. Most importantly, Pittsburgh Compound-B confirms the existence of Aβ plaques prior to the onset of dementia. This tracer is able to detect preclinical Alzheimer’s disease pathology with the same accuracy as seen in post-mortem examinations.

PET-amyloid plaque imaging with Pittsburgh Compound-B is shown to have a higher accumulation in subjects diagnosed with Alzheimer’s disease compared to patients with no dementia. Most importantly, Pittsburgh Compound-B confirms the existence of Aβ plaques prior to the onset of dementia. This tracer is able to detect preclinical Alzheimer’s disease pathology with the same accuracy as seen in post-mortem examinations.

PETamyloid imaging agent Vizamyl® (flutemetamol). This imaging agent differs slightly from the other FDA approval (April 2012) of Amyvid® because it is used to evaluate the density of plaques using a colour-calibrated scale of signal intensity.

Consequently, Amyvid® was approved using a grayscale. Amyvid®, like Pittsburgh Compound-B binds to beta-amyloid. However due to its longer half-life of 110 minutes it was found to accumulate more in the brains of people with Alzheimer’s disease, particularly in the regions known to be associated with beta-amyloid deposits.
PET imaging with $[^{18}F]DOPA$ can provide in vivo diagnostic information about the function of the pre-synaptic dopaminergic terminals. Other PET tracers that bind to pre-synaptic dopamine transporters include $[^{11}C]$methylphenidate and $[^{11}C]$ dihydrotetabenazine.27

Parkinson’s Disease (PD) is the result of loss of dopaminergic neurons in the substantia nigra. The greatest loss of neurons is seen in the ventrolateral tier of the pars compacta, with decreased involvement in the dorsomedial tier. The above regions can be detected by use of PET-[^{18}F]DOPA to indicate the $[^{18}F]$DOPA levels in the putamen contralateral area of the brain.28

Epilepsy

The application of PET-[^{18}F]FDG imaging in epileptic patients is to determine the regions of the brain which show epileptogenic foci. PET imaging using the radiotracer $[^{18}F]FDG$ was first introduced in the 1980s to study epilepsy following the observation of regional glucose hypo-metabolism in patients with partial seizures. PET-[^{18}F]FDG can detect the epileptogenic regions in patients with Temporal Lobe Epilepsy (TLE) reducing the need for Electroencephalogram (EEG) studies. PET can also measure the binding of specific radiotracers to ‘brain’ receptors which contribute to the formation of seizures. For example serotonin 5-HT$_{1A}$ receptor binding is shown to be decreased in TLE.29 PET-[^{18}F]FDG, to date, compared to MRI remains the most sensitive, non-invasive imaging tool for temporal lobe seizures.30

The PET radiotracer $[^{11}C]$flumazenil has been used to study the Benzodiazepine-receptor (BZD) in the role of epilepsy.31 These BZD receptors are situated in the same region as the γ-aminobutyric acid (GABA) receptors: the latter being the most important inhibitory neurotransmitters in the CNS. A reduction in $[^{11}C]$flumazenil binding has been observed at the mesial temporal lobe in TLE patients in the amygdale and hippocampus regions of the brain.

Multiple Sclerosis

The myelin PET radiotracer $[^{11}C]$MeDAS has been shown in animal models to penetrate the blood-brain barrier and therefore accumulate in regions of the brain indicating the presence of demyelination.32 Combinations of different PET radiotracers including $[^{18}F]$FDG, $[^{11}C]$PK11195 and $[^{11}C]$MeDAS contribute to the characterization of individual lesions; monitoring of temporal changes in multiple sclerosis and evaluation of treatment responses.33 A hybrid imaging approach using PET-MRI would provide a new approach to the formal diagnosis and treatment plan in patients with multiple sclerosis.34

CONCLUSION

In the near future PET imaging will become a routine diagnostic tool for many underlying neurological diseases such as dementia and Parkinson’s. PET imaging is playing a key role in the diagnosis of Alzheimer’s disease from the development of the radiotracer Pittsburgh Compound-B used to detect amyloid plaques in the brain. The FDA approval of Vizamyl® and Amyvid® to evaluate the density of plaques in the progression of Alzheimer’s disease has demonstrated the clinical application of PET neuro-imaging. Continued research and development in PET imaging will contribute to even earlier diagnosis of more disease states such as multiple sclerosis. This could potentially lead to a ‘personalized medicine’ culture which would be governed by our own genetic signature.

REFERENCES


